Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCLADRIBINE (cladribine) by Fresenius Kabi is synthesis, resulting in depletion of lymphocytes. Approved for ms [], relapsing form of multiple sclerosis (ms), to include relapsing-remitting disease in adults and 1 more indications. First approved in 2025.
Drug data last refreshed 1w ago
synthesis, resulting in depletion of lymphocytes.
Purine Antimetabolite
Worked on CLADRIBINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Cladribine Venetoclax in Monocytic AML
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo